Smart blood test guides lung cancer treatment in new trial
NCT ID NCT04841811
First seen May 13, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This phase 3 study tests a targeted drug called almonertinib in people with a specific type of advanced lung cancer (EGFR-mutant, stage III) that cannot be removed by surgery. After initial treatment, doctors use a sensitive blood test (MRD) to decide if more treatment is needed. The goal is to see if this approach can control the cancer longer and with fewer side effects. About 192 adults aged 18-70 are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Lung cancer institute
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.